Showing 7311-7320 of 8649 results for "".
- Paladin Phase 4 Study Confirms Iluvien Patients' Reduced Need for Multiple Treatmentshttps://modernod.com/news/paladin-phase-4-study-confirms-iluvien-patients-reduced-need-for-multiple-treatments/2481156/Alimera Sciences announced that post-hoc analyses from the PALADIN phase 4 safety study demonstrate that median treatment frequency in diabetic macular edema (DME) patients treated with the Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg was lower than from patients on other re
- SpyGlass Pharma Presents 3-Month Data from the First-In-Human Trial of Its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/SpyGlass Pharma announced 3-month data from a first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform lowered IOP in patients with open-angle glaucoma or ocular hypertension. The data were showcased during an oral presentation at the Eyecelerator inn
- Tarsus Presents Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Datahttps://modernod.com/news/tarsus-to-present-saturn-2-pivotal-phase-3-trial-data-and-saturn-1-extension-study-long-term-safety-data-at-upcoming-eye-care-meetings/2481123/Tarsus Pharmaceuticals announced that the results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming World Cornea Congress (WCC) VIII and the American Academy of Ophthalmology
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study
- Sight Sciences OMNI Surgical System to Be Featured in Multiple Presentations at the 2022 ESCRShttps://modernod.com/news/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-escrs/2481099/Sight Sciences announced that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting in Milan, Italy from September 16-20. At Sight Sciences Booth A2
- MeiraGTx’s Unveils Gene Therapy Manufacturing Facility in Shannon, Irelandhttps://modernod.com/news/meiragtxs-unveils-gene-therapy-manufacturing-facility-in-shannon-ireland/2481098/MeiraGTx Holdings will formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale ge
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- Zeiss Integrated Workflow Solutions Designed to Create Digital Transformation in Health Carehttps://modernod.com/news/zeiss-integrated-workflow-solutions-are-creating-the-digital-transformation-in-health-care/2481054/At Zeiss Innovation Week, taking place September 6-8, 2022, Zeiss Medical Technology will host experts in ophthalmology to share their personal experiences of how the power of integrated workflow solutions, data management, and a range of new software applications enable improved efficiencies and